4L9K
| X-ray study of human serum albumin complexed with camptothecin | Descriptor: | (2S)-2-hydroxy-2-[8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]butanoic acid, SERUM ALBUMIN | Authors: | Wang, Z, Ho, J.X, Ruble, J, Rose, J.P, Carter, D.C. | Deposit date: | 2013-06-18 | Release date: | 2013-07-24 | Last modified: | 2013-10-23 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim.Biophys.Acta, 1830, 2013
|
|
4LB2
| X-ray study of human serum albumin complexed with idarubicin | Descriptor: | IDARUBICIN, SERUM ALBUMIN | Authors: | Wang, Z, Ho, J.X, Ruble, J, Rose, J.P, Carter, D.C. | Deposit date: | 2013-06-20 | Release date: | 2013-07-24 | Last modified: | 2014-02-19 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim.Biophys.Acta, 1830, 2013
|
|
4LB9
| X-ray study of human serum albumin complexed with etoposide | Descriptor: | (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, MYRISTIC ACID, SERUM ALBUMIN | Authors: | Wang, Z, Ho, J.X, Ruble, J, Rose, J.P, Carter, D.C. | Deposit date: | 2013-06-20 | Release date: | 2013-07-24 | Last modified: | 2014-02-19 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim.Biophys.Acta, 1830, 2013
|
|
4L9Q
| X-ray study of human serum albumin complexed with teniposide | Descriptor: | (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-(thiophen-2-ylmethylidene)-beta-D-glucopyranoside, SERUM ALBUMIN | Authors: | Wang, Z, Ho, J.X, Ruble, J, Rose, J.P, Carter, D.C. | Deposit date: | 2013-06-18 | Release date: | 2013-07-24 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim.Biophys.Acta, 1830, 2013
|
|
4L8U
| X-ray study of human serum albumin complexed with 9 amino camptothecin | Descriptor: | (2S)-2-[1-amino-8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid, MYRISTIC ACID, Serum albumin | Authors: | Wang, Z, Ho, J.X, Ruble, J, Rose, J.P, Carter, D.C. | Deposit date: | 2013-06-17 | Release date: | 2013-07-24 | Last modified: | 2017-11-15 | Method: | X-RAY DIFFRACTION (2.01 Å) | Cite: | Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim.Biophys.Acta, 1830, 2013
|
|
4LA0
| X-ray study of human serum albumin complexed with bicalutamide | Descriptor: | R-BICALUTAMIDE, SERUM ALBUMIN | Authors: | Wang, Z, Ho, J.X, Ruble, J, Rose, J.P, Carter, D.C. | Deposit date: | 2013-06-18 | Release date: | 2013-07-24 | Last modified: | 2014-02-19 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim.Biophys.Acta, 1830, 2013
|
|
6XJA
| |
6XJB
| IgA1 Protease | Descriptor: | Immunoglobulin A1 protease | Authors: | Eisenmesser, E.Z, Zheng, H. | Deposit date: | 2020-06-23 | Release date: | 2020-12-09 | Last modified: | 2024-03-06 | Method: | ELECTRON MICROSCOPY (3.8 Å) | Cite: | Mechanism and inhibition of Streptococcus pneumoniae IgA1 protease. Nat Commun, 11, 2020
|
|
4GEV
| E. coli thymidylate synthase Y209W variant in complex with substrate and a cofactor analog | Descriptor: | 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID, 2'-deoxy-5'-uridylic acid, Thymidylate synthase | Authors: | Newby, Z, Lee, T.T, Finer-Moore, J, Stroud, R.M. | Deposit date: | 2012-08-02 | Release date: | 2012-08-29 | Last modified: | 2017-11-15 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | A remote mutation affects the hydride transfer by disrupting concerted protein motions in thymidylate synthase. J.Am.Chem.Soc., 134, 2012
|
|
6K4V
| The solution structure of the smart chimeric peptide G6 | Descriptor: | smart chimeric peptide G6 | Authors: | Wang, J.H, Liu, X.H. | Deposit date: | 2019-05-27 | Release date: | 2019-06-12 | Last modified: | 2023-06-14 | Method: | SOLUTION NMR | Cite: | Development of chimeric peptides to facilitate the neutralisation of lipopolysaccharides during bactericidal targeting of multidrug-resistant Escherichia coli. Commun Biol, 3, 2020
|
|
6K4W
| smart chimeric peptide SCP-A6 | Descriptor: | SCP-A6 | Authors: | Wang, J.H, Liu, X.H. | Deposit date: | 2019-05-27 | Release date: | 2019-06-12 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Development of chimeric peptides to facilitate the neutralisation of lipopolysaccharides during bactericidal targeting of multidrug-resistant Escherichia coli. Commun Biol, 3, 2020
|
|
7SYY
| Hendra virus G protein head domain in complex with cross-neutralizing murine antibody hAH1.3 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Antibody hAH1.3 Heavy Chain, ... | Authors: | Xu, K, Xu, Y. | Deposit date: | 2021-11-25 | Release date: | 2022-06-01 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.74 Å) | Cite: | Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant. Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
7SYZ
| Hendra virus G protein head domain in complex with cross-neutralizing murine antibody hAH1.3 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Antibody hAH1.3 Heavy Chain, Antibody hAH1.3 light chain, ... | Authors: | Xu, K, Xu, Y. | Deposit date: | 2021-11-25 | Release date: | 2022-06-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.86 Å) | Cite: | Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant. Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
6IWI
| Crystal structure of PDE5A in complex with a novel inhibitor | Descriptor: | MAGNESIUM ION, N-[3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidin-2-yl)-4-propoxyphenyl]-2-(4-methylpiperazin-1-yl)acetamide, ZINC ION, ... | Authors: | Zhang, X.L, Xu, Y.C. | Deposit date: | 2018-12-05 | Release date: | 2019-12-11 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.155 Å) | Cite: | Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. J.Med.Chem., 62, 2019
|
|
7XAF
| The crystal structure of TrkA kinase in complex with 4^6,14-dimethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-10-oxo-5-oxa-11,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclo- tetradecaphan-2-yne-45-carboxamide | Descriptor: | 4^6,14-dimethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-10-oxo-5-oxa-11,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclo-tetradecaphan-2-yne-45-carboxamide, High affinity nerve growth factor receptor | Authors: | Zhang, Z.M, Wang, Y.J. | Deposit date: | 2022-03-17 | Release date: | 2022-06-01 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (3.001182 Å) | Cite: | Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. J.Med.Chem., 65, 2022
|
|
7KDE
| |
8HK7
| Structure of PKD2-F604P (Polycystin-2, TRPP2) with ML-SA1 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-{2-oxo-2-[(4S)-2,2,4-trimethyl-3,4-dihydroquinolin-1(2H)-yl]ethyl}-1H-isoindole-1,3(2H)-dione, CALCIUM ION, ... | Authors: | Chen, M.Y, Su, Q, Wang, Z.F, Yu, Y. | Deposit date: | 2022-11-25 | Release date: | 2024-03-27 | Method: | ELECTRON MICROSCOPY (3 Å) | Cite: | Molecular and structural basis of the dual regulation of the polycystin-2 ion channel by small-molecule ligands. Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8VWP
| |
8TVB
| |
8TVI
| |
8GYX
| Cryo-EM structure of human CEPT1 | Descriptor: | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate, Choline/ethanolaminephosphotransferase 1, MAGNESIUM ION | Authors: | Qian, H.W, Wang, Z.H. | Deposit date: | 2022-09-24 | Release date: | 2023-03-22 | Last modified: | 2023-10-04 | Method: | ELECTRON MICROSCOPY (3.7 Å) | Cite: | Structural basis for catalysis of human choline/ethanolamine phosphotransferase 1. Nat Commun, 14, 2023
|
|
8GYW
| Cryo-EM structure of human CEPT1 complexed with CDP-choline | Descriptor: | Choline/ethanolaminephosphotransferase 1, MAGNESIUM ION, [2-CYTIDYLATE-O'-PHOSPHONYLOXYL]-ETHYL-TRIMETHYL-AMMONIUM | Authors: | Qian, H.W, Wang, Z.H. | Deposit date: | 2022-09-24 | Release date: | 2023-03-22 | Last modified: | 2023-10-04 | Method: | ELECTRON MICROSCOPY (3.9 Å) | Cite: | Structural basis for catalysis of human choline/ethanolamine phosphotransferase 1. Nat Commun, 14, 2023
|
|
8HN6
| Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD | Descriptor: | Heavy chain of monoclonal antibody 3G10, Light chain of monoclonal antibody 3G10, Spike protein S1 | Authors: | Qi, J, Chen, Y. | Deposit date: | 2022-12-07 | Release date: | 2023-05-17 | Last modified: | 2023-06-07 | Method: | X-RAY DIFFRACTION (2.07 Å) | Cite: | Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents. Front Immunol, 14, 2023
|
|
8HN7
| Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of monoclonal antibody 3C11, Light chain of monoclonal antibody 3C11, ... | Authors: | Qi, J, Chen, Y. | Deposit date: | 2022-12-07 | Release date: | 2023-05-17 | Last modified: | 2023-06-07 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents. Front Immunol, 14, 2023
|
|
7CUT
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with Z-VAD-FMK | Descriptor: | 3C protein, DIMETHYL SULFOXIDE, GLYCEROL, ... | Authors: | Lu, M, Yang, H.T, Wang, Z.Y, Zhao, Y, Xing, Y.F. | Deposit date: | 2020-08-24 | Release date: | 2021-06-23 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.82 Å) | Cite: | Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M pro . Signal Transduct Target Ther, 6, 2021
|
|